These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9811721)

  • 1. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.
    Spenlehauer C; Saragosti S; Fleury HJ; Kirn A; Aubertin AM; Moog C
    J Virol; 1998 Dec; 72(12):9855-64. PubMed ID: 9811721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.
    Vancott TC; Polonis VR; Loomis LD; Michael NL; Nara PL; Birx DL
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1379-91. PubMed ID: 8573396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.
    Robert-Guroff M; Louie A; Myagkikh M; Michaels F; Kieny MP; White-Scharf ME; Potts B; Grogg D; Reitz MS
    J Virol; 1994 Jun; 68(6):3459-66. PubMed ID: 7514675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.
    Beddows S; Louisirirotchanakul S; Cheingsong-Popov R; Easterbrook PJ; Simmonds P; Weber J
    J Gen Virol; 1998 Jan; 79 ( Pt 1)():77-82. PubMed ID: 9460926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.
    Warren RQ; Anderson SA; Nkya WM; Shao JF; Hendrix CW; Melcher GP; Redfield RR; Kennedy RC
    J Virol; 1992 Sep; 66(9):5210-5. PubMed ID: 1380094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization.
    Louisirirotchanakul S; Beddows S; Cheingsong-Popov R; Shaffer N; Mastro TD; Auewarakul P; Likanonsakul S; Wasi C; Weber J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):315-20. PubMed ID: 9833739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
    Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
    J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
    Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC
    J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
    Sherefa K; Sällberg M; Sönnerborg A
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
    Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
    J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
    J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
    Krachmarov CP; Kayman SC; Honnen WJ; Trochev O; Pinter A
    AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1737-48. PubMed ID: 11788025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.
    Pantophlet R; Aguilar-Sino RO; Wrin T; Cavacini LA; Burton DR
    Virology; 2007 Aug; 364(2):441-53. PubMed ID: 17418361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of primary isolate-like variants of simian-human immunodeficiency virus.
    Crawford JM; Earl PL; Moss B; Reimann KA; Wyand MS; Manson KH; Bilska M; Zhou JT; Pauza CD; Parren PW; Burton DR; Sodroski JG; Letvin NL; Montefiori DC
    J Virol; 1999 Dec; 73(12):10199-207. PubMed ID: 10559336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
    Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
    J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.
    Davis KL; Gray ES; Moore PL; Decker JM; Salomon A; Montefiori DC; Graham BS; Keefer MC; Pinter A; Morris L; Hahn BH; Shaw GM
    Virology; 2009 May; 387(2):414-26. PubMed ID: 19298995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.